Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study

Publisher: John Wiley & Sons Inc

E-ISSN: 1463-1326|20|2|344-351

ISSN: 1462-8902

Source: DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.20, Iss.2, 2018-02, pp. : 344-351

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content